Efficacy of Probiotic Therapy on Atopic Dermatitis in Children: A Randomized, Double-blind, Placebo-controlled Trial

Yang, Hyeon‐Jong; Min, Taek Ki; Lee, Hae Won; Pyun, Bok Yang

doi:10.4168/aair.2014.6.3.208

Cited by 60 publications

(64 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Importantly, these results were mainly obtained when probiotics were administered preventively in children at risk of developing the disease due to atopic heredity. Inconsistent data are presently available on the treatment with probiotics in established AD [24–27]. The probiotic approach is interesting but questionable because of the diversity and lack of standardization of the preparations used.…”

Section: Introductionmentioning

confidence: 99%

Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study

et al. 2017

View full text Add to dashboard Cite

BackgroundEnvironmental factors play a major role on atopic dermatitis (AD) which shows a constant rise in prevalence in western countries over the last decades. The Hygiene Hypothesis suggesting an inverse relationship between incidence of infections and the increase in atopic diseases in these countries, is one of the working hypothesis proposed to explain this trend.ObjectiveThis study tested the efficacy and safety of oral administration of the bacterial lysate OM-85 (Broncho-Vaxom®, Broncho-Munal®, Ommunal®, Paxoral®, Vaxoral®), in the treatment of established AD in children.MethodsChildren aged 6 months to 7 years, with confirmed AD diagnosis, were randomized in a double-blind, placebo-controlled trial to receive, in addition to conventional treatment with emollients and topical corticosteroids, 3.5mg of the bacterial extract OM-85 or placebo daily for 9 months. The primary end-point was the difference between groups in the occurrence of new flares (NF) during the study period, evaluated by Hazard Ratio (HR) derived from conditional Cox proportional hazard regression models accounting for repeated events.ResultsAmong the 179 randomized children, 170 were analysed, 88 in the OM-85 and 82 in the placebo group. As expected most children in both treatment groups experienced at least 1 NF during the study period (75 (85%) patients in the OM-85 group and 72 (88%) in the placebo group). Patients treated with OM-85 as adjuvant therapy had significantly fewer and delayed NFs (HR of repeated flares = 0.80; 95% confidence interval (CI): 0.67–0.96), also when potential confounding factors, as family history of atopy and corticosteroids use, were taken into account (HR = 0.82; 95% CI: 0.69–0.98). No major side effect was reported, with comparable and good tolerability for OM-85 and placebo.ConclusionsResults show an adjuvant therapeutic effect of a well standardized bacterial lysate OM-85 on established AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…plantarum, and Pediococcus pentosaceus, PRO-2 contained all PRO-1 components except L. acidophilus. According to clinical studies which used similar probiotics, compared to before and after treatment of probiotics, it shows that probiotics group were significantly increased in intestine (Yang et al, 2014;Yeun and Lee, 2014). Another studies show that different probiotics but, were similar results in the SD rats Lee et al, 2011).…”

Section: Discussionmentioning

confidence: 97%

Antiviral Properties of Probiotic Mixtures against Rotavirus in the Rat

Park¹,

Lee²,

Kim³

et al. 2014

The Korean Journal of Microbiology

View full text Add to dashboard Cite

Rotavirus is a major cause of acute gastroenteritis in young children in developed and developing countries. The use of probiotics for the treatment of gastrointestinal diseases is both safe and easily accessible. In this study, we evaluated the anti-rotaviral activities of probiotic mixtures in a Sprague-Dawley rat. 24 litters with their dams were randomly assigned to four groups; placebo, phosphate buffered saline (PBS), and two probiotic mixture (PRO-1 and PRO-2) groups. All rats were inoculated with rotavirus at dose of 8 log plaque forming units per rat at 5 days old. Animals in the PRO-1 and PRO-2 groups were orally administered probiotic mixtures 1 or 2, respectively, at a dose of 8 log colony forming units daily during 4 days. For control purposes, placebo and PBS groups were orally administered the same amount of placebo (containing maltose and polydextrose) or PBS once daily for 4 days, respectively. Antiviral analysis was performed by real-time quantitative PCR (RT-qPCR) and observing intestinal villi. As a result, weights of small intestines were greater in the PRO-1, PRO-2 groups than in control groups. Villi were short and villous epithelial necrosis was exhibited in control groups, but these morphological changes were not observed in PRO-1, PRO-2 treated rats. RT-qPCR analysis showed that VP7 gene level of rotavirus in fecal samples and small intestinal epithelial cells were lower in the PRO-1 and PRO-2 groups. These findings suggest that probiotic mixtures may be useful probiotics for the treatment of or as alternative therapies for rotaviral gastroenteritis.

show abstract

“…Although data on gut health in infants are scanty [12,13,15,16], many recent clinical trials suggest that probiotic administration in early infancy could be useful for the prevention and treatment of many disorders: modulation of the intestinal microbiota through use of probiotics has been suggested as strategy for preventing NEC, atopic eczema and managing infantile colic symptoms.…”

Section: Discussionmentioning

confidence: 99%

Probiotics and gut health in infants: A preliminary case–control observational study about early treatment with Lactobacillus reuteri DSM 17938

Savino

Fornasero

Ceratto

et al. 2015

Clinica Chimica Acta

View full text Add to dashboard Cite

AIMS: we performed this case-control observational study to evaluate the effects of early administration of Lactobacillus reuteri DSM 17938 on microbial composition in infants' gastrointestinal tract. METHODS: early fecal microbiota composition was analyzed by using selective and differential cultural methods. Genomic DNA from positive Escherichia coli and Cronobacter sakazakii colonies was extracted and DNA was processed by multiplex PCR assay. RESULTS: fecal samples of 30 hospitalized infants who previously received probiotics and 30 not receiving probiotics were analyzed. We find that the two groups showed differences in gut microbial strains composition and richness. Infant treated with probiotics have a lower total anaerobic gramnegative counts (p=0.03) and a higher total anaerobic gram-positive counts (p=0.02). Enterobacteriaceae and enterococci were significantly higher (p=0.04) in the control group. No significant differences were observed for total aerobic counts, lactobacilli and bifidobacteria. C. sakazaki was found only in one infant recruited in the control group. Infants not previously treated with probiotics showed a higher colonization by diarrheagenic E. coli (EPEC) (p=0.04). CONCLUSIONS: our findings enhanced our understanding of the effects of probiotics on gut health in pediatric subjects. Early administration of L.reuteri in infancy could improve gut health by reducing pathogens colonization. Our trial underlines the efficacy of an early probiotic administration in improving gut health in infancy.Informed consent was obtained from each child's parent.The study has been approved by a research ethics committee.There are no prior publications or submissions with any overlapping information, including studies and patients.These data have not been published previously and are not under consideration for publication by any other journal. The manuscript has not been and will not be submitted to any other journal while it is under consideration by Clinica Chimica Acta Journal.All authors have read and approved the version of the article being submitted.No an honorarium, grant, or other form of payment was given to anyone to produce the manuscript.All authors declare no conflict of interest.No affiliations with or financial involvement in any organization or entity with a direct financial interest in the subject matter or materials of the research discussed in the manuscript were present. Probiotics and gut health in infants: a case-control observational study about early treatment with Lactobacillus reuteri DSM 17938.

show abstract

Efficacy of Probiotic Therapy on Atopic Dermatitis in Children: A Randomized, Double-blind, Placebo-controlled Trial

Cited by 60 publications

References 26 publications

Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study

Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study

Antiviral Properties of Probiotic Mixtures against Rotavirus in the Rat

Probiotics and gut health in infants: A preliminary case–control observational study about early treatment with Lactobacillus reuteri DSM 17938

Contact Info

Product

Resources

About